07/27 Taiwan BIO Weekly
2026-07-27 |
| Taiwan BIO Weekly |
| TCM Biotech Reports Positive Interim Phase III Analysis Results for U101, Aims for Full Patient Enrollment 24 July, 2026 TCM Biotech (TW: 4169) announced significant progress from the interim analysis of its Taiwan Phase III clinical trial of U101, a novel therapy for preventing recurrent urinary tract infections (UTIs). Following an independent review, the trial was confirmed to have an acceptable overall safety profile, and recommended to continue according to the original protocol. TCM Biotech said it will continue efforts to complete enrollment of the target 348 participants. According to the trial design, the interim analysis was triggered after 60% of participants (208 patients) completed 24 weeks of treatment or experienced at least one UTI recurrence. More... (in Chinese) |
| Bora Pharmaceuticals Partners with Onconic Therapeutics to Enter US Market 24 July, 2026 Bora Pharmaceuticals (TW: 6472) announced that its US Maple Grove facility has secured its first CDMO order from an Asian innovative drug company, being Korea-based Onconic Therapeutics' GERD treatment JAQBO in US clinical development and commercialization. The partnership marks another step in Bora Pharmaceutical's strategy to help Asian pharmaceutical companies expand into the US market. JAQBO, a potassium-competitive acid blocker (P-CAB) developed for gastroesophageal reflux disease, received South Korean marketing approval in 2024 and became the country's 37th domestically developed innovative drug. More... (in Chinese) |
| HanchorBio Reports Positive Clinical Data for HCB101 23 July, 2026 HanchorBio (TW: 7827) announced positive new clinical data for its lead anticancer candidate, HCB101, reporting a 54.5% objective response rate (6 of 11 patients achieved a partial response) and a 100% disease control rate in a second-line colorectal cancer study. The results further support the company's core development strategy for second-line gastric and gastroesophageal junction cancers while highlighting the potential to expand into additional gastrointestinal cancer indications. HCB101 is a CD47 immune checkpoint inhibitor designed to restore macrophages' ability to recognize and eliminate cancer cells, and HanchorBio is actively evaluating the drug in combination with standard therapies to develop a versatile macrophage-based immunotherapy platform. More... (in Chinese) |
| AnHorn Medicines Completes First Patient Dosing in Phase I Trial, Aims to Develop World's First Drug for Chemotherapy-Induced Neuropathy 23 July, 2026 AnHorn Medicines announced today (23rd of July) that its first-in-class neuroprotective drug candidate AH-008 has completed first patient dosing in a Phase I clinical trial. The candidate is being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN), and the milestone marks the official entry of this innovative therapy into clinical development, offering a potential new solution for one of the most common and debilitating complications experienced by cancer patients. More... (in Chinese) |
| PharmaEssentia Expands Ropeg Presence into Macau 22 July, 2026 PharmaEssentia (TW: 6446) announced that it has submitted an application to Macau's Pharmaceutical Administration Bureau to expand the indication of BESREMi (Ropeg) for adult patients with essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea (HU) treatment. Having already secured approval in Macau for polycythemia vera (PV), the new application aims to broaden Ropeg's use in myeloproliferative neoplasms (MPN) and further strengthen the company's presence in the Macau market. More... (in Chinese) |
| Japan's DCI Partners Sees Strong Potential in Three Taiwanese Biotech Sectors, Pledges to Foster Collaboration 21 July, 2026 Japanese venture capital firm DCI Partners (Daiwa Corporate Investment) has actively invested in Taiwan's biotechnology sector in recent years. Following the successful close of its Japan-Taiwan Biotech Fund III at approximately NT$4 billion in early July, DCI Partners President Hiroki Narita said the firm sees strong investment opportunities in Taiwan's regenerative medicine, smart healthcare, and health data sectors. Looking ahead, DCI Partners plans to actively facilitate the IPOs of Japanese biotech companies in Taiwan, creating business opportunities worth tens of billions of NT$ through cross-border collaboration. More... (in Chinese) |
| Taiwan's Next Healthcare Leap: Turning Biomedical Innovation into Patient Impact 21 July, 2026 Speaking during BIO Asia-Taiwan 2026, Shih-Chia Lin of FMPAT outlines how Taiwan can harness its strengths in clinical medicine, biotechnology and digital technology to build a more preventive, connected and patient-centered healthcare ecosystem. More... |
| TaiRx's ADC Drug Candidate Draws Interest from Three Global Pharma Companies; First Trial Enrollment Completed 21 July, 2026 TaiRx (TW: 6580) announced today (21st of July) that, leveraging its research foundation in CVM-1118, it has developed a novel ADC payload candidate, CVM-1125, which has attracted significant interest, with three global pharma companies having signed confidentiality agreements (NDAs) with TaiRx to explore potential collaborations. Meanwhile, the company's anti-cancer drug candidate CVM-1118 has successfully initiated a Phase II liver cancer clinical trial in China, with the first cohort of patients enrolled. More... (in Chinese) |
| Locus Cell and Pegatron Sign MOU to Develop Digital Twin Model for Cell Manufacturing Facility 21 July, 2026 Locus Cell (TW: 6891) announced today (21st of July) that it has signed a memorandum of understanding (MOU) with Pegatron (TW: 4938) to jointly develop a smart GMP cell manufacturing facility. Locus Cell stated that the collaboration demonstrates Taiwan's successful integration of semiconductor and AI-driven automation technologies into the biopharmaceutical sector, while establishing a new milestone for smart cell manufacturing. More... (in Chinese) |
| SMOBIO Technology to List on Emerging Stock Market 20 July, 2026 SMOBIO Technology (TW: 7422), a biotech subsidiary of Global Lighting Technologies (TW: 4935), is set to list on Taiwan's Emerging Stock Market on July 24. Specializing in life science reagents and biotech raw materials, SMOBIO will expand production capacity through strategic collaboration with Global Lighting Technologies to build an efficient, high-quality supply platform. More... (in Chinese) |
| Protect Animal Health Targets US$49 Billion Pet Gene Therapy Market with Canine In Vivo CAR-T Platform 20 July, 2026 Protect Animal Health (TW: 7850) has partnered with US biotech company Coastar Therapeutics and Synergy Biomedical to develop the world's first in vivo CAR-T gene therapy for dogs. The collaboration combines Coastar's erythrocyte membrane-based gene delivery platform with cell therapy and veterinary drug development technologies to target pet cancers, autoimmune diseases, genetic disorders, and neurodegenerative diseases, tapping into the US$49 billion global pet gene therapy market. More... (in Chinese) |
| BIO Asia-Taiwan's Global Influence Now Rivals BIO Europe, Driving Billion-Dollar Business Opportunities 20 July, 2026 BIO Asia-Taiwan Chairman Johnsee Lee said yesterday (19th of July) that, after years of growth, BIO Asia-Taiwan has successfully transformed from a regional exhibition in Taiwan into Asia's leading international biotechnology event, with an industry influence now on par with BIO Europe. More... (in Chinese) |
| Taiwan Innovation Board Welcomes Second Stock to Break NT$1,000 Mark; Pell Bio-Med Hits Limit-Up at NT$1,025 with Foreign Investors Buying NT$285 Million 16 July, 2026 Taiwan's Innovation Board has welcomed its second stock to surpass the NT$1,000 threshold. Cell therapy drug developer Pell Bio-Med (TW: 6949) surged by its daily limit on July 15 to close at NT$1,025, pushing its market capitalization to a record NT$67.2 billion (approximately US$2.1 billion). Foreign investors were a key driver, purchasing 280 lots for a total of NT$285 million (approximately US$8.9 million), marking a single-day buying high over the past year, with cumulative net purchases in 2026 approaching NT$500 million (approximately US$15.6 million). Coinciding with the BIO Asia-Taiwan Exhibition, the Innovation Board has become the highest-valuation cluster for Taiwan's biotech industry. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |